🚀 VC round data is live in beta, check it out!

BillionToOne Valuation Multiples

Discover revenue and EBITDA valuation multiples for BillionToOne and similar public comparables like Hamamatsu Photonics, LivaNova, ICU Medical, Sectra and more.

BillionToOne Overview

About BillionToOne

BillionToOne Inc is a precision diagnostics company revolutionizing molecular testing with its patented Quantitative Counting Templates (QCT) platform. This technology enables ultrasensitive, single-molecule DNA quantification, making genetic testing more accurate, affordable, and accessible. The company serves prenatal screening and oncology markets with non-invasive tests that detect fetal genetic risks and monitor cancer therapy response.


Founded

2016

HQ

United States

Employees

N/A

Financials (LTM)

Revenue: $340M
EBITDA: $41M

EV

$4B

Valuation Multiples

Multiples.vc

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

BillionToOne Financials

BillionToOne reported last 12-month revenue of $340M and EBITDA of $41M.

In the same LTM period, BillionToOne generated $233M in gross profit, $41M in EBITDA, and $9M in net income.

Revenue (LTM)


BillionToOne P&L

In the most recent fiscal year, BillionToOne reported revenue of $305M and EBITDA of $37M.

BillionToOne expects next 12-month revenue of XXX and NTM EBITDA of XXX

See BillionToOne forward-looking valuation multiples
LTMNTMLast FYFY 2026FY 2027FY 2028
Revenue$340MXXX$305MXXXXXXXXX
Gross Profit$233MXXX$208MXXXXXXXXX
Gross Margin69%XXX68%XXXXXXXXX
EBITDA$41MXXX$37MXXXXXXXXX
EBITDA Margin12%XXX12%XXXXXXXXX
EBIT Margin5%XXX5%XXXXXXXXX
Net Profit$9MXXX$7MXXXXXXXXX
Net Margin3%XXX2%XXXXXXXXX

Financial data powered by Morningstar, Inc.

BillionToOne Stock Performance

BillionToOne has current market cap of $4B, and enterprise value of $4B.

Market Cap Evolution


BillionToOne's stock price is $80.83.

See BillionToOne trading valuation data
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$4B$4B0.0%XXXXXXXXX$0.16

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

BillionToOne Valuation Multiples

BillionToOne trades at 10.6x EV/Revenue multiple, and 89.0x EV/EBITDA.

See valuation multiples for BillionToOne and 15K+ public comps

EV / Revenue (LTM)


BillionToOne Financial Valuation Multiples

As of April 8, 2026, BillionToOne has market cap of $4B and EV of $4B.

Equity research analysts estimate BillionToOne's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

BillionToOne has a P/E ratio of 403.1x.

LTMNTMLast FYFY 2026FY 2027FY 2028
Market cap (current)$4BXXX$4BXXXXXXXXX
EV (current)$4BXXX$4BXXXXXXXXX
EV/Revenue10.6xXXX11.8xXXXXXXXXX
EV/EBITDA89.0xXXX96.8xXXXXXXXXX
EV/EBIT197.8xXXX225.5xXXXXXXXXX
EV/Gross Profit15.5xXXX17.3xXXXXXXXXX
P/E403.1xXXX496.3xXXXXXXXXX
EV/FCF241.9xXXX230.5xXXXXXXXXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified BillionToOne Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

BillionToOne Margins & Growth Rates

BillionToOne's revenue in the last 12 month grew by 39%.

BillionToOne's rule of 40 is 54% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

BillionToOne's rule of X is 119% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for BillionToOne and other 15K+ public comps

BillionToOne Operational Valuation Multiples

LTMNTMLast FYFY 2026FY 2027FY 2028
Revenue Growth39%XXX43%XXXXXXXXX
EBITDA Margin12%XXX12%XXXXXXXXX
EBITDA Growth47%XXX33%XXXXXXXXX
Rule of 40—XXX54%XXXXXXXXX
Bessemer Rule of X—XXX119%XXXXXXXXX
S&M Expenses to Revenue32%XXX33%XXXXXXXXX
G&A Expenses to Revenue15%XXX14%XXXXXXXXX
R&D Expenses to Revenue17%XXX16%XXXXXXXXX
Opex to Revenue—XXX63%XXXXXXXXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

BillionToOne Public Comps

See public comps and valuation multiples for other Diagnostics & Genomics and Medical Devices comps.

EV/RevenueEV/EBITDA
LTM2026E2027ELTM2026E2027E
Hamamatsu PhotonicsXXXXXXXXXXXXXXXXXX
LivaNovaXXXXXXXXXXXXXXXXXX
ICU MedicalXXXXXXXXXXXXXXXXXX
SectraXXXXXXXXXXXXXXXXXX
MGI TechXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXX

Valuation data powered by FactSet, Inc.

BillionToOne M&A Activity

BillionToOne acquired XXX companies to date.

Last acquisition by BillionToOne was on XXXXXXXX, XXXXX. BillionToOne acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

See M&A valuation multiples

Latest Acquisitions by BillionToOne

Acquired CompanyValuationEV/RevenueEV/EBITDA
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.

Start Free Trial

BillionToOne Investment Activity

BillionToOne invested in XXX companies to date.

BillionToOne made its latest investment on XXXXXXXX, XXXXX. BillionToOne invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).

See VC round multiples

Latest Investments by BillionToOne

CompanyValuationEV/RevenueEV/EBITDA
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About BillionToOne

When was BillionToOne founded?BillionToOne was founded in 2016.
Where is BillionToOne headquartered?BillionToOne is headquartered in United States.
Is BillionToOne publicly listed?Yes, BillionToOne is a public company listed on Nasdaq.
What is the stock symbol of BillionToOne?BillionToOne trades under BLLN ticker.
When did BillionToOne go public?BillionToOne went public in 2025.
Who are competitors of BillionToOne?BillionToOne main competitors are Hamamatsu Photonics, LivaNova, ICU Medical, Sectra.
What is the current market cap of BillionToOne?BillionToOne's current market cap is $4B.
What is the current revenue of BillionToOne?BillionToOne's last 12 months revenue is $340M.
What is the current revenue growth of BillionToOne?BillionToOne revenue growth (NTM/LTM) is 39%.
What is the current EV/Revenue multiple of BillionToOne?Current revenue multiple of BillionToOne is 10.6x.
Is BillionToOne profitable?Yes, BillionToOne is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of BillionToOne?BillionToOne's last 12 months EBITDA is $41M.
What is BillionToOne's EBITDA margin?BillionToOne's last 12 months EBITDA margin is 12%.
What is the current EV/EBITDA multiple of BillionToOne?Current EBITDA multiple of BillionToOne is 89.0x.
What is the current FCF of BillionToOne?BillionToOne's last 12 months FCF is $15M.
What is BillionToOne's FCF margin?BillionToOne's last 12 months FCF margin is 4%.
What is the current EV/FCF multiple of BillionToOne?Current FCF multiple of BillionToOne is 241.9x.

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial